Cirius Therapeutics, Inc.
Cirius Therapeutics is a clinical-stage pharmaceutical company dedicated to developing innovative therapies for diseases caused by insulin resistance, including Type 2 Diabetes and Obesity. Their focus is on restoring insulin response and re-balancing mitochondrial metabolism to improve glycemic control, increase lean muscle mass, and shift fat tissue to more metabolically beneficial forms. They are advancing a next-generation oral insulin sensitizer, azemiglitazone (MSDC-0602K), which targets the mitochondrial pyruvate carrier (MPC) to address metabolic dysfunction at its root.
Industries
Nr. of Employees
small (1-50)
Cirius Therapeutics, Inc.
Patents
Thiazolidinedione analogs for the treatment of NAFLD and metabolic diseases
US-11931345-B2
View DetailsPPAR-sparing thiazolidinedione salts for the treatment of metabolic diseases
US-9126959-B2
View DetailsPPAR-sparing thiazolidinedione salts for the treatment of metabolic diseases
US-8912335-B2
View Details
Thiazolidinedione analogs for the treatment of NAFLD and metabolic diseases
US-11931345-B2
View DetailsPPAR-sparing thiazolidinedione salts for the treatment of metabolic diseases
US-9126959-B2
View DetailsPPAR-sparing thiazolidinedione salts for the treatment of metabolic diseases
US-8912335-B2
View DetailsProducts
Once-daily oral MPC-targeting insulin sensitizer (small molecule)
A once-daily oral small-molecule therapeutic designed to modulate the mitochondrial pyruvate carrier to improve insulin sensitivity, glycemic control, reduce fatty liver, and favorably alter body composition.
Once-daily oral MPC-targeting insulin sensitizer (small molecule)
A once-daily oral small-molecule therapeutic designed to modulate the mitochondrial pyruvate carrier to improve insulin sensitivity, glycemic control, reduce fatty liver, and favorably alter body composition.
Services
Collaborations with academic laboratories to perform mechanistic preclinical studies and combination-therapy evaluations in metabolic disease models.
Collaborations with academic laboratories to perform mechanistic preclinical studies and combination-therapy evaluations in metabolic disease models.
Expertise Areas
- Insulin resistance therapeutics
- Metabolic disease drug development (T2D, obesity, MASH)
- Preclinical pharmacology and translational studies
- Clinical trial design and execution (Phase 2b, Phase 3 readiness)
Key Technologies
- Mitochondrial pyruvate carrier (MPC) targeting
- Oral small-molecule insulin sensitizers
- Preclinical rodent models (db/db mice)
- Biomarker assessment (HbA1c, fasting insulin, liver histology)
News & Updates
Cirius Therapeutics will present at the WuXi Global Forum during J.P. Morgan Healthcare Week, showcasing their latest developments.
A late-breaking poster at EASL 2024 demonstrates that azemiglitazone, in combination with GLP-1 receptor agonists, can preserve lean muscle and improve metabolic parameters.
This content discusses the presentation of data on azemiglitazone combined with GLP-1 receptor agonists, highlighting its potential benefits in preserving lean muscle and improving metabolic health.
Cirius Therapeutics will present at the WuXi Global Forum during J.P. Morgan Healthcare Week, showcasing their latest developments.
A late-breaking poster at EASL 2024 demonstrates that azemiglitazone, in combination with GLP-1 receptor agonists, can preserve lean muscle and improve metabolic parameters.
This content discusses the presentation of data on azemiglitazone combined with GLP-1 receptor agonists, highlighting its potential benefits in preserving lean muscle and improving metabolic health.